Cancer Patients Receiving Myelosuppressive Chemotherapy: FILGRASTIM (LEUCOGEN) is indicated in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia and fever. A complete blood count (CBC) and platelet count should be obtained prior lo chemotherapy, and twice per week during FILGRASTIM (LEUCOGEN) therapy to avoid leukocytosis and to monitor the neutrophil count.
FILGRASTIM (LEUCOGEN) therapy should be discontinued when the ANC is >10,000/mm3 after the expected chemotherapy-induced nadir.
Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy: FILGRASTIM (LEUCOGEN) is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML.
Cancer Patients Receiving Bone Marrow Transplant: FILGRASTIM (LEUCOGEN) is Indicated to reduce the duration of neutropenia and neutropenia-related clinical squeal, eg, febrile neutropenia, in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation. It is recommended that blood cells and platelet counts be obtained at a minimum of 3 times per week following marrow infusion to monitor the recovery of marrow reconstitution.
Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy: FILGRASTIM (LEUCOGEN) is indicated for the mobilization of haematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilization allows for the collection of increased numbers of progenitor cells capable of engraftment after myeloablative chemotherapy.
Patients With Severe Chronic Neutropenia: FILGRASTIM (LEUCOGEN) is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (eg, fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia. It is essential that serial cell blood counts with differential and platelet counts, and an evaluation of bone marrow morphology and karyotype be performed prior to initiation of FILGRASTIM (LEUCOGEN) therapy. The use of FILGRASTIM (LEUCOGEN) prior to confirmation of SCN may impair diagnostic efforts and may thus impair or delay evaluation and treatment of an underlying condition causing the neutropenia.
Pediatric Use In Severe Chronic Neutropenia and Cancer: FILGRASTIM (LEUCOGEN) is indicated for the treatment of the conditions previously described in pediatric patients. The efficacy and safety of FILGRASTIM (LEUCOGEN) are similar for adults and infants.